araag2/HINT huggingface dataset:
Clinical trial NCT00696384 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: azilsartan medoxomil, azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin ii receptor blocker antihypertensive medications., placebo
SMILES: CC(=O)NC1=NN=C(S1)S(N)(=O)=O, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          1. Has essential hypertension (diastolic blood pressure ≥ 95mm Hg and ≤ 119 mm Hg. For
             participants with diabetes or chronic kidney disease diastolic blood pressure must be
             ≥ 85 mm Hg and ≤ to 109 mm Hg.

          2. Female participant is not of childbearing potential (eg, sterilized, postmenopausal).

          3. Female participants of childbearing potential who are sexually active must agree to
             use adequate contraception, and can neither be pregnant nor lactating from Screening
             throughout the duration of the study.

          4. Clinical laboratory evaluations (including clinical chemistry, hematology, and
             complete urinalysis) are within the reference range for the testing laboratory unless
             the results are deemed not clinically significant for inclusion into this study by the
             investigator.

        Exclusion Criteria

          1. Systolic blood pressure greater than 185 mm Hg.

          2. Is required to take or intends to continue taking any disallowed medication, any
             prescription medication, herbal treatment or over-the counter medication that may
             interfere with evaluation of the study medication, including:

          3. Is hypersensitive to AII receptor blockers.

          4. Recent history (within the last 6 months) of myocardial infarction, unstable angina,
             coronary artery bypass graft, percutaneous coronary intervention, cerebrovascular
             accident, or transient ischemic attack.

          5. History of moderate to severe heart failure or hypertensive encephalopathy.

          6. Has clinically significant cardiac conduction defects (eg, third-degree
             atrioventricular block, sick sinus syndrome).

          7. Has secondary hypertension of any etiology.

          8. Known or suspected unilateral or bilateral renal artery stenosis.

          9. Has severe renal dysfunction or disease (based on calculated creatinine clearance < 30
             mL/min/1.73 m2) at Screening.
Clinical trial NCT00355589 (phase 3, status: completed)
Conditions: hypertension, blood pressure, high
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: ramipril and hydrochlorothiazide
SMILES: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Previously diagnosed, or newly diagnosed essential hypertension. Blood pressure must
             be within a minimum and maximum range prior to drug treatment.

        Exclusion Criteria:

          -  Inability to discontinue all prior antihypertensive medications

          -  Heart failure

          -  History of stroke, myocardial infarction, or chest pain within 3 years, or an abnormal
             heart rhythm

          -  Liver or kidney disease

          -  Certain drugs used to treat other conditions like an enlarged prostate gland, or
             arthritis

          -  Allergy or reactions to certain medications used to treat high blood pressure

        Other protocol-defined inclusion and exclusion criteria apply.
Clinical trial NCT00673231 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, dapagliflozin, placebo, dapagliflozin, dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes

          -  Patients with HbA1c ≥7.5% and ≤10.5% and who are on a stable insulin regimen of at
             least 30 IU of injectable insulin per day either without any other oral antidiabetic
             drug or with a stable dose of oral antidiabetic drugs

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Treatment with more than two additional oral antidiabetic drugs

          -  Moderate and severe renal (kidney) failure or dysfunction
Clinical trial NCT00405704 (phase 3, status: completed)
Conditions: vesicoureteral reflux, urinary tract infections
ICD codes: N13.71, N13.70, N13.721, N13.722, N13.729, N13.731, N13.732, P39.3, N39.0, O86.20, O86.29, N99.531, O03.38, N99.521
Drugs: trimethoprim-sulfamethoxazole, placebo
SMILES: CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age at randomization: at least 2 months, but less than 6 years of age. Note that
             children as young as 1 month were screened for the study.

          -  Diagnosed first or second febrile or symptomatic UTI within 112 days prior to
             randomization

          -  Presence of Grade I- IV VUR based on radiographic voiding cystourethrogram (VCUG)
             performed within 112 days of diagnosis of index UTI.

          -  Appropriately treated index febrile or symptomatic UTI

        Exclusion Criteria:

          -  Index UTI diagnosis more than 112 days prior to randomization

          -  History of more than two UTIs prior to randomization

          -  For patients less than 6 months of age at randomization, gestational age less than 34
             weeks

          -  Co-morbid urologic anomalies

          -  Hydronephrosis, SFU Grade 4

          -  Ureterocele

          -  Urethral valve

          -  Solitary kidney

          -  Profoundly decreased renal size unilaterally on ultrasound (based on 2 standard
             deviations below the mean for age and length) performed within 112 days after
             diagnosis of index UTI

          -  Multicystic dysplastic kidney

          -  Neurogenic bladder

          -  Pelvic kidney or fused kidney

          -  Known sulfa allergy, inadequate renal or hepatic function, Glucose-6-phosphate
             dehydrogenase deficiency or other conditions that are contraindications for use of
             TMP-SMZ

          -  History of other renal injury/disease

          -  Unable to complete the study protocol

          -  Congenital or acquired immunodeficiency

          -  Underlying anomalies or chronic diseases that could potentially interfere with
             response to therapy such as chronic gastrointestinal conditions (i.e., malabsorption,
             inflammatory bowel disease), liver or kidney failure, or malignancy.

          -  Complex cardiac disease as defined in the Manual of Procedures.

          -  Any known syndromes associated with VUR or bladder dysfunction

          -  Index UTI not successfully treated

          -  Unlikely to complete follow-up

          -  Family history of anaphylactic reaction to sulfa medications
Clinical trial NCT00256698 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant, anastrozole
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent, postmenopausal females, histological or cytological confirmed
             oestrogene and/or progesterone (PgR) receptor positive breast cancer, local recurrence
             or metastasis

        Exclusion Criteria:

          -  Previous systemic endocrine therapy for advanced or recurrent disease; prior
             fulvestrant therapy

          -  Premenopausal women
Clinical trial NCT00087711 (phase 3, status: completed)
Conditions: non small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: pemetrexed, gemcitabine, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of NSCLC Stage IIIB not amenable to curative treatment or Stage IV.

          -  No prior chemotherapy for lung cancer.

          -  Patients must have at least one uni-dimensionally measurable lesion.

          -  Prior radiation therapy to less than 25% of bone marrow, whole pelvis not allowed.
             Radiation must be completed at least 4 weeks prior to study enrollment.

        Exclusion Criteria:

          -  Treatment with any drug within the last 30 days that has not received regulatory
             approval.

          -  Serious cardiac condition.

          -  Serious medical disorder in addition to NSCLC that would make it difficult for the
             patient to complete the study.

          -  Inability or unwillingness to take folic acid or Vitamin B12 supplementation.

          -  Presence of fluid retention that cannot be controlled by drainage.
Clinical trial NCT00355862 (phase 3, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cni, mmf, steroids, aza etc. (mtor inhibitor free), sirolimus
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 years and older

          2. Histologically proven HCC before randomisation

          3. Signed, written informed consent

        Exclusion Criteria:

          1. Multiple-organ recipients.

          2. Known hypersensitivity to sirolimus or its derivatives.

          3. Hyperlipidemia refractory to optimal medical management. (cholesterol >300 mg/dL;
             triglycerides >350 mg/dL).*

          4. Evidence of significant local or systemic infection.

          5. Known HIV-positive patients.*

          6. Platelets <75,000/cubic mm.*

          7. Women of child-bearing potential not willing to take contraception.

          8. Patients with non-HCC malignancies within the past 5 years,excluding successfully
             treated squamous cell carcinoma and basal cell carcinoma of the skin.

          9. Extrahepatic HCC tumor manifestation

         10. Patients with a psychologic, familial, sociologic or geographic condition potentially
             hampering compliance with the study protocol and follow-up schedule.

         11. Patients under guardianship (e.g. individuals who are not able to freely give their
             informed consent).
Clinical trial NCT00699374 (phase 3, status: terminated)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sunitinib malate, sorafenib
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically-confirmed diagnosis of hepatocellular carcinoma

          -  presence of measurable disease by radiographic imaging

          -  Child-Pugh class A

          -  ECOG PS 0 or 1

          -  adequate organ function.

        Exclusion Criteria:

          -  Prior treatment with any systemic treatment for hepatocellular carcinoma

          -  prior local treatment within 4 weeks from entry

          -  presence of clinically relevant ascites

          -  severe hemorrhage <4 weeks of starting study treatment

          -  known HIV or serious acute or chronic illness

          -  current treatment on another clinical trial

          -  pregnancy or breastfeeding
Clinical trial NCT00563368 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: vi-0521, vi-0521, topiramate, topiramate, phentermine, phentermine, vi-0521
SMILES: CC(C)(N)CC1=CC=CC=C1, CC(C)(N)CC1=CC=CC=C1, [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, CC(C)(N)CC1=CC=CC=C1, CC(C)(N)CC1=CC=CC=C1, CC(C)(N)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  70 years of age or less with body mass index (BMI) between 30 and 45 kg/m2

          -  Informed Consent

          -  Females of child-bearing potential must be using adequate contraception

        Exclusion Criteria:

          -  Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  Glaucoma or elevated intraocular pressure

          -  Pregnancy or breastfeeding

          -  Drug or Alcohol abuse

          -  Smoking cessation within previous 3 months or plans to quit smoking during study

          -  Eating disorders within past year

          -  Cholelithiasis within past 6 months

          -  Type 2 diabetes

          -  Previous bariatric surgery

          -  Bipolar disorder or psychosis

          -  Steroid hormone therapy not stable for 3 months

          -  Systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg
Clinical trial NCT01539512 (phase 3, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: idelalisib, rituximab, placebo to match idelalisib
SMILES: [H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1, ClCCN(CCCl)P1(=O)NCCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion:

          -  Adult subjects with previously treated recurrent CLL who have measurable
             lymphadenopathy

          -  Require therapy for CLL

          -  Have experienced CLL progression < 24 months since the completion of the last prior
             therapy

          -  Currently not sufficiently fit to receive cytotoxic therapy because of
             chemotherapy-induced bone marrow damage or comorbidities.
Clinical trial NCT00423319 (phase 3, status: completed)
Conditions: deep vein thrombosis, pulmonary embolism
ICD codes: I82.491, I82.492, I82.493, I82.499, I82.591, I82.592, I82.593, I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: enoxaparin, apixaban, enoxaparin-matching placebo, apixaban-matching placebo
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria

          -  Patients undergoing elective unilateral total hip replacement or a revision of at
             least 1 component of a total hip replacement.

          -  Patients who were willing and able to undergo bilateral ascending contrast venography

          -  Either sex, any race, 18 years and older

        Key Exclusion Criteria

          -  Known or suspected bleeding or coagulation disorder in the patient or his or her
             first-degree relative

          -  Known or suspected history of heparin-induced thrombocytopenia

          -  Known coagulopathy

          -  Active bleeding or at high risk for bleeding

          -  Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days

          -  Active hepatobiliary disease

          -  Alcohol and/or substance abuse within the past year

          -  Any condition for which surgery or administration of an anticoagulant is
             contraindicated

          -  Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic
             blood pressure >180 mm Hg or supine diastolic blood pressure >105 mm Hg

          -  Clinically significant laboratory abnormalities at the enrollment visit:

          -  Hemoglobin <10 g/dL

          -  Platelet count <100,000/mm^3

          -  Creatinine clearance <30 mL/min, as estimated by the method of Cockcroft and Gault

          -  Alanine aminotransferase or aspartate aminotransferase >2*upper limit of normal or a
             total bilirubin ≥ 1.5*1 (unless an alternative causative factor such as Gilbert's
             syndrome was identified)

          -  Need for ongoing treatment with a parenteral or oral anticoagulant (eg, subjects with
             mechanical valves, warfarin eligible atrial fibrillation)

          -  Current use of dextrans or fibrinolytics

          -  Treatment with medications affecting coagulation or platelet function
Clinical trial NCT01462929 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium bromide, tiotropium, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD
             guidelines).

          -  Post-salbutamol (FEV1) < 80% and ≥ 30% of predicted normal value and Post-salbutamol
             FEV1/FVC < 70%.

          -  Current or ex-smokers of 10 ≥pack-years.

        Exclusion Criteria:

          -  Patients with no history or current diagnosis of asthma.

          -  No evidence of an exacerbation within 6 weeks prior to the screening visit.

          -  No evidence of clinically significant respiratory and/or cardiovascular conditions or
             laboratory abnormalities.

          -  No contraindication to use of anticholinergic drugs such as known symptomatic
             prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.
Clinical trial NCT00656578 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: 4975, placebo
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 years and older.

          -  Planning to undergo unilateral transpositional first metatarsal osteotomy for
             correction of Hallux Valgus Deformity (referred to as bunionectomy in this protocol).

        Exclusion Criteria:

          -  Use of certain medications or having a medical condition that in the investigator's
             opinion could adversely impact the patient's participation or safety, conduct of the
             study, or interfere with the pain assessments.

          -  Diabetes mellitus with a known HbA1C > 9.5 or a history of prolonged uncontrolled
             diabetes.

          -  Participated in another clinical trial or used an investigational product within 30
             days prior to the planned bunionectomy surgery, or is scheduled to receive an
             investigational product other than 4975 while participating in the study.

          -  Previously participated in a clinical study with 4975.
Clinical trial NCT00053976 (phase 3, status: completed)
Conditions: graft versus host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: methylprednisolone, placebo
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  Allogeneic Transplantation

          -  Acute GVHD requiring therapy (skin stage 2 or overall grade II-IV)

          -  Signed, informed consent

        Exclusion Criteria

          -  Mental or emotional contraindications as determined by patient's physician

          -  Steroids given prophylactically or therapeutically at a dose > 1 mg/kg/d
             methylprednisolone (including prevention of acute GVHD or treatment for diffuse
             alveolar hemorrhage and severe obstructive mucositis within 7 days prior to starting
             acute GVHD therapy. Steroids administered as amphotericin premedication are allowed if
             below 1 mg/kg/day.

          -  Acute GVHD diagnosed solely by virtue of upper GI GVHD

          -  Hypersensitivity to Daclizumab or prior therapy with Daclizumab

          -  GVHD from donor lymphocyte infusion

          -  Other investigational therapeutics within 30 days of enrollment

          -  Pregnancy or of fertile, failure to agree to use contraception
Clinical trial NCT01202084 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: formoterol/fluticasone, foraseq®, fluticasone
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Sign the ICF

          -  Age ≥ 12 years

          -  Persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18
             with symptoms for at least 6 months and clinically stable for at least 1 month, with
             the ACQ-745 test (see Appendix C) ≤ 3.0

          -  Current use of inhaled corticosteroid (beclomethasone dipropionate dose of up to 1000
             µg), associated or not with long-term β2-adrenergic agents and breakthrough medication
             (salbutamol or equivalent)

          -  Initial FEV1 of at least 40% of the predicted normal value

          -  Serum cortisol assessment within normal values.

        Exclusion Criteria:

          -  Use of oral or parenteral corticosteroid within the 3 months prior to study beginning

          -  Requirement of admission due to asthma within the 3 months prior to study beginning

          -  Presence of active smoking, defined as the use of cigarette, pipe, cigar or any form
             of smoking at any amount within the last 3 months

          -  Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological,
             neoplastic, hematological, infectious, dermatological, neurological, psychiatric or
             chronic respiratory disease other than asthma

          -  Recent (< 6 months) or predicted participation during this study in other clinical
             studies involving drugs of any nature or in studies of any form of intervention for
             treating asthma

          -  Intolerance or allergy to any of the components of the drugs assessed in the study

          -  Pregnancy or lactation

          -  Chronic use of β-blocker medications, per routine oral or intravenous route, or also
             as ophthalmic solutions